Leukemia Genetic Profile - Any 6 Markers PCR Qualitative Test
Short Name: Leukemia Genetic Profile PCR
Also known as: Leukemia Gene Panel PCR, Leukemia Mutation Panel Qualitative, Hematologic Malignancy Gene Profile, Leukemia Molecular Markers Test, Six-Marker Leukemia PCR Panel
Leukemia Genetic Profile - Any 6 Markers PCR Qualitative Test test available at DNA Labs India for ₹9,500. Uses Real Time PCR (Polymerase Chain Reaction) on Whole Blood / Bone Marrow Aspirate samples. Results in Sample collection days: Tuesday and Friday (by 11:00 AM). Report delivery: Thursday and Monday respectively. Reports are available via online portal, email, and WhatsApp.. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr SULOCHANA HEMCHANDRA HOLLA
Consultant Medical Geneticist · Reg: 8532
Last reviewed: September 7, 2026
Overview
The primary purpose of the Leukemia Genetic Profile - Any 6 Markers PCR Qualitative Test is to identify specific genetic mutations and chromosomal abnormalities associated with leukemia. This test aids in confirming a leukemia diagnosis, determining the subtype of leukemia, performing risk stratification to predict disease behavior, guiding targeted therapy selection, and monitoring minimal residual disease in some contexts. By detecting the presence or absence of key molecular markers, clinicians can make more informed treatment decisions and improve patient outcomes.
- Test Code
- 1169
- CPT Code
- 81206
- ICD Code
- C95.9
- Price
- ₹9,500
- Sample Type
- Whole Blood / Bone Marrow Aspirate
- Result Time
- Sample collection days: Tuesday and Friday (by 11:00 AM). Report delivery: Thursday and Monday respectively. Reports are available via online portal, email, and WhatsApp.
- Fasting Required
- No
- Method
- Real Time PCR (Polymerase Chain Reaction)
Sample Collection
No special preparation such as fasting is required. Provide a brief clinical history including suspected diagnosis, prior treatment history, and any previous genetic test results. Specify the six markers to be tested on the Test Request Form. Ensure the patient is not on anticoagulant therapy that may affect sample quality, or note this on the requisition.
Method: Venipuncture / Bone Marrow Aspiration
Laboratory Analysis
Collect 3 mL (minimum 2 mL) of whole blood via venipuncture into a Lavender Top (EDTA) tube. Alternatively, a bone marrow aspirate sample may be collected in an EDTA tube by a qualified physician. Label the sample correctly with patient details, date, and time of collection. Gently invert the tube 8-10 times to mix with anticoagulant.
Report Delivery
Ship the sample refrigerated at 2-8°C. Do not freeze the sample. Ensure the sample reaches the laboratory within 48 hours of collection. Maintain the cold chain during transportation.
Timeline: Sample collection days: Tuesday and Friday (by 11:00 AM). Report delivery: Thursday and Monday respectively. Reports are available via online portal, email, and WhatsApp.
Patient Instructions
About This Test
Who Should Get This Test
The primary purpose of the Leukemia Genetic Profile - Any 6 Markers PCR Qualitative Test is to identify specific genetic mutations and chromosomal abnormalities associated with leukemia. This test aids in confirming a leukemia diagnosis, determining the subtype of leukemia, performing risk stratification to predict disease behavior, guiding targeted therapy selection, and monitoring minimal residual disease in some contexts. By detecting the presence or absence of key molecular markers, clinicians can make more informed treatment decisions and improve patient outcomes.
How to Prepare
- Collect 3 mL (2 mL min.) whole blood or bone marrow aspirate in a Lavender Top (EDTA) tube
- Gently invert the EDTA tube 8-10 times immediately after collection
- Ship refrigerated at 2-8°C. Do not freeze
- Ensure sample reaches the lab within 48 hours of collection
- Specify the 6 selected markers on the Test Request Form
- Attach brief clinical history and suspected diagnosis
- Label the tube clearly with patient name, date of birth, date and time of collection
Doctor's Notes
Reviewed by Dr SULOCHANA HEMCHANDRA HOLLA — MBBS, MD (Medical Genetics) · Reg. No. 8532
"Molecular profiling of leukemia using targeted PCR panels is a cornerstone of modern hematologic oncology. Identifying specific genetic markers such as BCR-ABL1, FLT3, NPM1, and others enables precise risk stratification and guides targeted therapy selection. This qualitative six-marker panel offers a rapid, cost-effective approach for initial diagnostic workup and can significantly influence treatment protocols. I recommend this test for any patient with newly diagnosed or relapsed leukemia where molecular characterization is clinically indicated."
Last medically reviewed: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Sample received in heparinized tube instead of EDTA
- Clotted or hemolyzed sample
- Sample volume less than 2 mL
- Sample received without proper labeling or identification
- Sample older than 48 hours at the time of receipt
- Frozen sample
- Test Request Form without specified markers or clinical history
Understanding Your Results
Confirms the presence of the Philadelphia chromosome translocation t(9;22). Consistent with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive ALL. Patient may benefit from tyrosine kinase inhibitor (TKI) therapy such as imatinib, dasatinib, or nilotinib.
Action: Refer to hematologist/oncologist for treatment initiation with TKIs and quantitative BCR-ABL1 monitoring.
Indicates presence of FLT3-ITD or FLT3-TKD mutation, commonly seen in AML. Associated with aggressive disease and poor prognosis. Targeted FLT3 inhibitors such as midostaurin or gilteritinib may be indicated.
Action: Urgent oncology referral for risk-adapted therapy including consideration of FLT3 inhibitors and allogeneic stem cell transplantation.
NPM1 mutation in the absence of FLT3-ITD is associated with a favorable prognosis in AML. This finding may influence consolidation therapy decisions.
Action: Discuss with oncologist for treatment stratification. Additional testing for FLT3 status is recommended if not already evaluated.
Confirms acute promyelocytic leukemia (APL), a medical emergency requiring immediate treatment initiation with all-trans retinoic acid (ATRA) and arsenic trioxide.
Action: Initiate ATRA immediately upon clinical suspicion even before confirmatory results. Urgent hematology referral.
Indicates core-binding factor AML (CBF-AML) with generally favorable prognosis. High-dose cytarabine-based consolidation is typically recommended.
Action: Oncology referral for treatment planning. Consider KIT mutation testing for additional prognostic information.
IDH mutations are found in a subset of AML and may serve as therapeutic targets. Targeted therapies such as enasidenib (IDH2) and ivosidenib (IDH1) are available.
Action: Discuss targeted therapy options with oncologist. IDH mutation status may also serve as a marker for measurable residual disease monitoring.
None of the six selected genetic markers were detected. This does not rule out leukemia or other genetic abnormalities. Further workup including cytogenetics, FISH, next-generation sequencing panels, and bone marrow biopsy may be warranted.
Action: Discuss with treating physician for additional diagnostic testing as clinically indicated.
Consult your hematologist or oncologist immediately if you are experiencing persistent fatigue, unexplained weight loss, frequent infections, easy bruising or bleeding, bone pain, swollen lymph nodes, or night sweats. If your test results show detection of any genetic marker, urgent medical consultation is required to discuss treatment options. If all markers are negative but clinical suspicion remains high, further diagnostic workup should be discussed with your physician.
Limitations
- ⚠This is a qualitative test and does not provide mutation burden or allele frequency
- ⚠Only the six markers selected at the time of ordering will be evaluated
- ⚠A negative result does not exclude the presence of other genetic mutations associated with leukemia
- ⚠Results should be interpreted in conjunction with clinical findings, morphology, immunophenotyping, and other laboratory data
- ⚠Sensitivity may vary depending on the proportion of leukemic cells in the sample
- ⚠This test is not suitable for monitoring minimal residual disease where quantitative sensitivity is required
Risks & Considerations
- ●Minor bruising or soreness at the blood collection site
- ●Rare risk of infection at the puncture site
- ●If bone marrow aspirate is collected, there may be localized pain, minor bleeding, or very rarely infection at the aspiration site
Interfering Factors
- ●Heparin contamination of the sample can interfere with PCR amplification
- ●Degraded or insufficient DNA due to improper sample handling or storage
- ●Sample collected in incorrect tube type (non-EDTA)
- ●Extremely low white blood cell count may affect DNA yield
- ●Recent blood transfusion may dilute leukemic cell population in the sample
Compare With Similar Tests
| Test | Leukemia Genetic Profile - Any 6 Markers PCR Qualitative Test | BCR-ABL1 Quantitative PCR Test | Next-Generation Sequencing (NGS) Hematologic Malignancy Panel | Fluorescence In Situ Hybridization (FISH) Panel for Leukemia | Flow Cytometry Immunophenotyping |
|---|---|---|---|---|---|
| Comparison | Leukemia Genetic Profile - Any 6 Markers PCR Qualitative Test | The BCR-ABL1 quantitative PCR test measures the exact amount of BCR-ABL1 fusion gene and is used for monitoring treatment response in CML, whereas the Leukemia Genetic Profile provides qualitative detection for initial diagnosis and screening across multiple markers. | NGS panels can detect hundreds of mutations simultaneously with high sensitivity and provide quantitative variant allele frequency, but are more expensive and have longer turnaround times. The PCR-based six-marker panel offers a rapid, cost-effective option for targeted mutation screening. | FISH detects chromosomal translocations and numerical abnormalities at the chromosomal level and can be performed on interphase cells. PCR-based testing offers higher sensitivity for specific known mutations but does not detect novel or cryptic rearrangements that FISH may identify. | Flow cytometry identifies leukemia subtypes based on cell surface and intracellular markers (immunophenotype) and is essential for lineage determination. The PCR genetic profile complements immunophenotyping by providing molecular-level information that influences prognosis and therapy selection. |
Frequently Asked Questions
What is the Leukemia Genetic Profile - Any 6 Markers PCR Qualitative Test?
Which genetic markers can be selected for this test?
What sample is required for this test?
Is fasting required before this test?
How is this test different from a complete blood count (CBC)?
What does it mean if a genetic marker is detected?
What if all six markers are not detected?
How long does it take to get the test results?
Is home sample collection available for this test?
What is the cost of the Leukemia Genetic Profile PCR test?
Can this test be used to monitor treatment response?
Who should get this test done?
Related Tests
B-Cell Rearrangement Detection Test
₹22,000Acute Lymphoblastic Leukemia (ALL) Cytogenetics Panel Test
₹20,000Epstein-Barr Virus Early RNA (EBER-ISH) In-Situ-Hybridization Test
₹6,000OncoPro NCCN Lung Cancer Panel with PD-L1 Test
₹140,400Acute Myeloid Leukemia (AML) Cytogenetics Panel Test
₹23,000AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test
₹6,000Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.